One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...

Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...

Q3 2024 Earnings Call Transcript November 12, 2024 Megan LeDuc: Good evening. I’m Megan LeDuc, Manager of Investor Relations ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors. Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks (DNA) reported strong Q3 results driven by $45M in released deferred revenues from the terminated contract with Motif, and cost ...

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

Boston-based Ginkgo Bioworks has canceled plans to move into a 250K SF lab data center and will exit two Cambridge locations ...

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...